Vir Biotechnology (VIR) Q2 FY26 earnings call

Vir Biotechnology reported strong Q2 FY26 results, driven by significant collaboration revenue from Astellas, substantially improving its cash position and net income. The company made meaningful progress across its pipeline, completing enrollment for all registrational Hepatitis Delta ECLIPPS studies with key readouts expected soon, and accelerating the oncology program VIR5500 into expansion cohorts with Astellas, targeting Phase 3 next year. The focus remains on advancing both programs towards regulatory submissions and commercial readiness.